Comparison of two formulations of intravenous lipid emulsions in pediatric intestinal failure
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Apr 2024 · 1 min read
In brief
In brief
This retrospective study compared soybean oil versus mixed oil lipid emulsions in 79 pediatric intestinal failure patients. While both formulations showed similar rates of IFALD incidence and resolution, mixed oil emulsion was associated with faster IFALD resolution and improved weight gain.
- Mixed oil lipid emulsion (ML) and soybean oil emulsion (SL) showed similar rates of IFALD incidence and resolution in pediatric IF patients.
- ML was administered at higher doses than SL (median 2 vs 1 g/kg/day) without increasing IFALD risk.
- IFALD resolved nearly twice as fast with ML compared to SL (67 vs 37 days median time to resolution).
- Patients receiving ML demonstrated superior weight gain compared to SL cohort at 1-year follow-up.
- ML may offer clinical advantages in growth outcomes and faster IFALD resolution despite similar overall IFALD rates in pediatric IF.
Written by the GCMD Library team from the article.
Abstract
Purpose
The effect of different types of lipid emulsion may guide therapy of patients with intestinal failure (IF) to limit morbidity such as intestinal failure-associated liver disease (IFALD).
Methods
A retrospective chart review of pediatric patients with IF who received soybean oil lipid emulsion (SL) or mixed oil lipid emulsion (ML) was performed. Data over 1 year were collected.
Results
Forty-five patients received SL and 34 received ML. There were no differences in the incidence (82 versus 74%, P = 0.35) or resolution (86 versus 92%, P = 0.5) of IFALD between the cohorts. The median dose of ML was higher compared to SL (2 versus 1 g/kg/day, P < 0.001). If resolved, IFALD resolved rapidly in the ML cohort compared to the SL cohort (67 versus 37 days, P = 0.01). Weight gain was higher in the ML compared to the SL cohort at resolution of IFALD or 1 year from diagnosis of IF (P = 0.009).
Conclusion
The administration of ML did not alter the incidence or resolution of IFALD compared to SL in pediatric IF. There was rapid resolution of IFALD and enhanced weight gain in the ML cohort compared to SL in pediatric IF.